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The aim of present research was investigation of anticancer activity of 4-azolidinone-3-carboxylic acids
derivatives, and studies of structure–activity relationships (SAR) aspects. Methods. Organic synthesis;
spectral methods; anticancer screening was performed according to the US NCI protocol (Developmental
Therapeutic Program). Results. The data of new 4-thiazolidinone-3-alkanecarboxylic acids derivatives in
vitro anticancer activity were described. The most active compounds which belong to 5-arylidene-2,4-
thia(imida)zolidinone-3-alkanecarboxylic acids; 5-aryl(heteryl)idenerhodanine-3-succinic acids deriva-
tives were selected. Determination of some SAR aspects which allowed to determine directions in lead-
compounds structure optimization, as well as desirable molecular fragments for design of potential
anticancer agents based on 4-azolidinone scaffold were performed. 5-Arylidenehydantoin-3-acetic acids
amides were identified as a new class of significant selective antileukemic agents. Possible pharmacophore
scaffold of 5-ylidenerhodanine-3-succinic acids derivatives was suggested. Conclusions. The series of
active compounds with high anticancer activity and/or selectivity levels were selected. Some SAR aspects
were determined and structure design directions were proposed.
Keywords: 4-azolidinone-3-carboxylic acids, anticancer activity, SAR.
Introduction. Design of «small molecules» as innova-
tive anticancer agents based on well-known scaffolds is 
one of the most commonly employed approaches in
drug discovery. Nowadays the anticancer potential of
4-azolidinone-3-carboxylic acids (derivatives of rho-
danine, 2,4-thiazolidindione or hydantoin with carbo-
xylic acids in position N3) realized via influence on
various metabolic pathways of cancer cells is described 
based on traditional and high-throughput screening [1,
2] (Fig. 1). The large group of mentioned heterocycles
with known pharmacological activity (such as antioxi-
dant, anti-inflammatory, hypoglycemic, immunomo-
dulative, etc.) was established as promising anticancer
agents as well. Another approach to search of anti-
cancer substances is target-oriented drug design, which 
allows to identify anticancer hit-compounds among
4-azolidinone-3-carboxylic acids derivatives [6]. Con-
sequently, the row of 4-azolidinone-3-carboxylic acids
derivatives with high affinity to «anticancer biotar-
gets» was discovered. 5-Arylidenerhodanine-3-carbo-
xylic acids are known as inhibitors of antiapoptic pro-
tein–protein interaction between Bcl-2 and Bax family
and their interaction with receptors’ domains [7–10];
inhibitors of JSP-1 – «atypical» dual-specific phospha-
tases family member (JNK-stimulating phosphatase-1)
[11]. Among 4-azolidinone-3-carboxylic acids COX
inhibitors are selected [12] because of their potential
anticancer activity [6]. Hydantoin-carboxylic acids are
inhibitors of Ras farnesyl transferase [13] and are con-
sidered to be perspective anticancer agents [14]. The
ligands of neuroimunofiline FK506-binding protein
(FKBP) are structurally analogous to mentioned series
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alkancarboxylic acids belong to a new group of non-
covalent inhibitors of Human Leukocyte Elastase [16] .
There is known antiproliferative potential of 5-
substituted N-derivatives of hydantoin [17] and 5-ary-
lidene-2,4-imidazolidinediones [18], which are related
to EGFR-kinase (epidermal growth factor receptor)
inhibition [19–21]. Among amides of latter acids the
inhibitors of cyclin-depended kinase (CDK2/Cyclin A) 
[22] are selected. One of the discovered molecular me-
chanisms of 4-azolidinone-3-carboxylic acids is anta-
gonism to avb3-receptors. Inhibitor possibility was im-
proved based on correlation between expression fac-
tor progression and cancer development [23]. 
Also anticancer activity of 5-substituted 4-azoli-
dinone-carboxylic acids are associated with p53 depen- 
dent pathways of apoptotic and neoplastic trans-
formation  [24] and inhibition of necroptosis (regulated
caspase-independent cell death mechanism) [25].
Extensive research has been directed towards hypoxia-
based strategies for anticancer agents [6]. 5-Ylidene-
rhodanines, which may be interpreted as synthetic pre-
cursors of rhodanine-3-carboxylic acids, modulate pro- 
liferation and apoptosis of cancer cells via influence on
NO-related pathways [5]. There is an interesting fact of
combined anti-inflammatory, antioxidant, and other
related activities established for some compounds [26,
27], which is extremely important within the classical
progression triad: stress–inflammation–cancer.
In the light of search for new 4-azolidinone-3-
carboxylic acids derivatives as potential anticancer
agents the present work was aimed to investigation of
anticancer activity of newly synthesized compounds
and studies of some structure-activity relationships
aspects.
Materials and methods. For anticancer activity
screening the library of 4-azolidinone-3-carboxylic
acids was previously synthesized [1, 28–30] using kno- 
wn synthetic methods. Synthetic approaches to target
compounds differed and depended on nature of core
heterocycles (rhodanine, 2,4-thiazolidinedione, hydan- 
toin). Compounds of rhodanine row were synthesized
by modification of rhodanine-3-carboxylic acids. Deri- 
vatives of acids belonged to 2,4-thia(imida)zolidinedi-
one series were synthesized on the assumption of 2,4-
thiazolidinedione or hydantoin rings. 5-Ylidenederiva- 
tives of mentioned compounds were obtained by dif-
ferent modifications of Knoevenagel reaction (Fig. 2).
The structures and purity of synthesized compo-
unds were elucidated by spectral data (
1H NMR, IR, EI- 
MS, LC-MS).
Newly synthesized compounds were selected by
the National Cancer Institute (NCI) Developmental
Therapeutic Program (www.dtp.nci.nih.gov) for the in
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Fig. 1. Structure of 4-azolidinone derivatives with anticancer activity138
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Fig. 3. Structure of selected samples for advanced anticancer screening (against the full panel of about 60 human tumor cell lines at 10-fold
dilutions of five concentrations ranging from 10
–4 to 10
–8 M)
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Fig. 2. General synthetic schemevitro cell line screening to investigate their anticancer
activity. Anticancer assays were performed according
to the US NCI protocol as described elsewhere [31–
34]. The compounds were first evaluated at one dose
primary anticancer assay towards three cell lines (panel 
consisting of three types of human cancers: breast
(MCF7), lung (NCI-H460) and CNS (SF-268) – con-
centration 10
–4 M) or towards approximately 60 cell li-
nes (concentration 10
–5 M). The human tumor cell lines
were derived from nine different cancer types: leuke-
mia, melanoma, lung, colon, CNS, ovarian, renal, pro-
state and breast cancers. In the screening protocol, each 
cell line was inoculated and pre-incubated for 24–48 h
on a microtiter plate. 
Test agents were then added at a single
concentration and the culture was incubated for further
48 h. End point determinations were made with a
protein binding dye, sulforhodamine B (SRB). Re-
sults for each test agent were reported as the percent
growth of the treated cells when compared to the un-
treated control cells. A 48 h continuous drug exposure
protocol was used with a SRB protein assay to estimate
cell viability and growth. 
The cytotoxic and/or growth inhibitory effects of
the most active selected compounds were tested in vitro
against the full panel of about 60 human tumor cell
lines at 10-fold dilutions of five concentrations ranging 
from 10
–4 to 10
–8 M. Using the seven absorbance measu- 
rements [time zero (Tz), control growth in the absence
of drug (C), and test growth in the presence of drug at
the five concentration levels (Ti)], the percentage gro-
wth was calculated at each of the drug concentrations
levels. Percentage growth inhibition was calculated as: 
[Ti – Tz/C – Tz] × 100 for concentrations for which Ti ³ Tz;
[Ti – Tz/Tz] × 100 for concentrations for which Ti < Tz.
Three dose response parameters were calculated for 
each compound. Growth inhibition of 50 % (GI50) was
calculated from [(Ti – Tz)/(C – Tz)] × 100 = 50, which is
the drug concentration resulting in a 50 % lower net
protein increase in the treated cells (measured by SRB
staining) as compared to the net protein increase seen in 
the control cells. The drug concentration resulting in
total growth inhibition (TGI) was calculated from Ti =
= Tz. The LC50 (concentration of drug resulting in a
50 % reduction in the measured protein at the end of the 
drug treatment as compared to that at the beginning)
indicating a net loss of cells following treatment was
calculated from [(Ti – Tz)/Tz] × 100 = –50. Values were
calculated for each of these three parameters if the level 
of activity is reached; however, if the effect was not
reached or was exceeded, the value for that parameter
was expressed as greater or less than the maximum or
minimum concentration tested. The lgGI50, lgTGI,
lgLC50 were then determined, defined as the mean of
the log’s of the individual GI50, TGI, LC50 values. The
lowest values are obtained with the most sensitive cell
lines. Furthermore, mean graph midpoints (MG_MID)
were calculated for each of the parameters, giving an
average activity parameter over all cell lines for each
compound. For the calculation of the MG_MID, in-
sensitive cell lines were included with the highest
concentration tested.
Results and discussion. During the first step of
screening (using one concentration) on 3 cancer cell
lines (MCF7, NCI-H460, SF-268) 49 compounds were
tested. For mentioned samples different levels of anti-
mitotic activity were established, thought in the
majority of cases the maximum influence was observed 
against NCI-H460 line Non-small cell lung cancer line. 
32 Compounds were tested using 60 cancer cell lines
panel. Average values of panel cancer lines growth per- 
cent lay within 100 %, which provides evidence that
nonspecific antimitotic action for studied 4-thiazoli-
dinone derivatives. However, tested compounds pos-
sessed specific influence on some individual cell lines
without influencing others. This fact may be related to
effect on some metabolic pathways or biotarget of
certain cell lines (www.dtp.nci.nih.gov; http://www.lg
cpromochem-atcc.com). UO-31 and 786-O renal can-
cer cell lines have been found to be the most sensitive to 
testing compounds. For example 3-[3-(3-trifluoro-
methylphenyl)-[1,2,4]-triazolo-[3,4-b][1,3,4]-thiadia-
zol-6-yl-methyl]-thiazolidine-2,4-dione, 2-[2,4-dioxo- 
5-(3,4,5-trimethoxybenzylidene)-thiazolidin-3-yl]-N-
(4-sulfamoylphenyl)-acetamide, 3-[5-(4-methoxyben-
zylidene)-4-oxo-2-thioxothiazolidin-3-yl]-1-(3-triflu-
oromethylphenyl)-pyrrolidine-2,5-dione and 2-(4-ben- 
zylidene-2,5-dioxoimidazolidin-1-yl)-N-(4-chloro-
phenyl)-acetamide provided not only growth inhibition 
but also death of UO-31 cells. The same effect was ob-
139
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Com-
pound
logGI50 logGI50 logGI50
N 1 Range
a MG_MID N 2 Range
a MG_MID N 3 Range
a MG_MID
1 2 3 4 5 6 7 8 9 10
1 50 <–8.00  ¸ –5.17 –6.26 50 –6.85 ¸ –4.70 –5.31 29 –5.73 ¸ –4.08 –4.37
Most sensitive cell lines (logGI50/logTGI): MOLT-4 –7,80/–6,85; SR  < –8,00/–6,85 (L); SW-620 < –8,00/–6,57 (CC); 
SF 539 < –8,00/–6,57 (CNS)
2 28 –5.22 ¸ –4.36 4.60 9 –4.63 ¸ > –4.30 –4.34 – > –4.30 4.30
Most sensitive cell lines (logGI50/logTGI): HL-60 (TB) –5.22/–4.32; K-562 –5.16/–4.59; RPMI-8226 –5.10/–4.47 (L); 
NCI-H460 –5.20/–4.49; NCI-H522 –5.12/> –4.30 (NSCLC); KM12 –5.07/> –4.30 (CC); LOX IMVI –5.00/–4.51 (M);
OVCAR-3 –5.14/–4.50 (OC); MDA-MB-435 –5.02/–4.51 (BC)
3 28 –6.21 ¸ > –4.30 –4.64 4 –5.39 ¸ > –4.30 –4.35 – > –4.30 –4.30
Most sensitive cell lines (logGI50/logTGI): A549/ATTC –5.41/> –4.30; NCI-H460 –5.30/> –4.30 (NSCLC); 
HCT-116 –5.38/> –4.30 (CC); U251 –5.36/> –4.30 (CNS); SK-MEL5 –6.21/–5.39 (M); ACHN –5.08/> –4.30; 
SN12C –5.20/> –4.30 (RC); MCF-7 –5.06/> –4.30; MDA-MB-231/ATTC –5.19/>  –4.30 (BC)
4 46 –5.88 ¸ > –4.30 –4.77 17 –5.53 ¸ > –4.30 –4.38 1 –4.43 ¸ > –4.30 –4.30
Most sensitive cell lines (logGI50/ logTGI): CCRF-CEM –4.95/> –4.30 (L); SF 539 –5.88/–5.53; U251 –5.34/–4.74 (CNS);
LOX IMVI –5.10/–4.48; SK-MEL2 –5.25/–4.52; UACC62 –5.02/–4.46 (M); OVCAR-8 –5.05/> –4.30 (OC); 
ACHN –5.00/–4.45; UO31 –5.01/–4.36 (RC); DU-145 –5.03/> –4.30 (PC); MDA-MB-231/ATTC –5.09/–4.57 (BC)
5 49 <–8.30 ¸ > –4.30 –4.78 24 –6.45 ¸ > –4.30 –4.42 4 –4.62 ¸ > –4.30 –4.31
Most sensitive cell lines (logGI50/logTGI): RPMI-8226 –4.99/> –4.30 (L); NCI-H23 –4.97/–4.69; 
NCI-H522 –4.90/–4.56 (NSCLC); HCT-116  –4.94/–4.58 (CC); U251 –4,95/> –4.30 (CNS);  SK-MEL5 < –8.30/–6.45 (M);
OVCAR-8 –4.92/–4.47 (OC); ACHN –4.99/–4.69 (RC)
6 19 –6.08 ¸ > –4.30 –4.55 5 –5.79 ¸ > –4.30 –4.36 – > 4.30 –4.30
Most sensitive cell lines(logGI50/logTGI): SR  –5.21/> –4.30 (L); NCI-H23 –5.09/–4.35 (NSCLC); 
U-251 –4.82/> –4.30 (CNS); LOX IMVI –5.93/–5.53 (M); UO-31 –6.08/–5.79 (RC)
7 38 –6.17 ¸ –4.02 –4.47 17 –5.41 ¸ –4.18 –4.14 8 –4.30 ¸ –4.05 –4.03
Most sensitive cell lines (logGI50/logTGI): CCRF-CEM –5.36/–5.41; RPMI8226 –6.17/–5.41; MOLT-4  –5.41/–4.00 (L);
OVCAR-8 –5.16/> –4.00 (OC)
8 8
10*
–6.05 ¸ –4.01
  –7.71 ¸ –4.10*
–4.26
  –4.17*
5
  3*
–5.85 ¸ –4.01
  –5.51 ¸ –4.62*
–4.09
  –4.05*
3
  2*
–5.02 ¸ –4.53
  –4.28 ¸ –4.09*
–4.05
  –4.01*
Most sensitive cell lines (logGI50/logTGI): CCRF-CEM –6.06 (5.92*)/> –4.00 (–5.51*); HL-60 (TB) –6.53/––5.70; 
K-562 –5.68 (–5.27*)/> –4.00 (> –4.00*); MOLT-4 –6.52 (–5.34*)/–5.49 (–4.62*); SR –6.51 (–7.71*)/–5.85 (–4.90*) (L);
HOP-92 –4.74/–4.01 (NSCLC)
9 53 –5.15 ¸ –4.04 –4.57 29 –4.55 ¸ –4.09 –4.16 6 –4.22 ¸ –4.14 –4.01
Most sensitive cell lines (logGI50/logTGI): CCRF-CEM –4.83/–4.50; HL-60 (TB) –4.71/–4.33; MOLT-4 –4.96/–4.55;
RPMI-8226 –4.68/–4.17; SR –5.15/–4.47 (L); HOP-62 –4.82/–4.36; HOP-92 –4.76/–4.38; NCI-H226 –4.80/–4.35 (NSCLC); 
SF-268 –4.98/–4.53, SF-539 –4.78/–4.41: SNB –4.88/–4.44; U251 –4.83/–4.53 (CNS); LOX-IMVI –4.81/–4.49 (M);
OVCAR-4 –4.88/–4.19; SK-OV-3  –4.71/–4.29 (OC); SN-12C –4.77/–4.32; TK-10 –4.77/–4.37 (RC);  MDA-MB-231/ATTC 
–4.79/–4.37; HS-578T  –4.97/–4.42 (BC)
10 16 –5.55 ¸ –4.11 –4.12 5 –4.23 ¸ –4.02 –4.01 0 – –4.00
Most sensitive cell lines (logGI50/logTGI): NCI NCI-H23 –4.58/–4.05 (NSCLC);  HCT-116 –4.52/> –4.00 (CC); 
U251 –4.59/–4.16 (CNS); OVCAR-3 –4.51/–4.02 (OC); MCF-7 –5.55/> –4.00; MDA-MB-231/ATTC –4.63/–4.23 (BC)
Summary of anticancer activity of the compounds in different concentrations (10
–4–10
–8 M) towards 60 cancer cell lines141
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1 2 3 4 5 6 7 8 9 10
11 22 –5.57 ¸ –4.07 –4.28 7 –4.78 ¸ –4.04 –4.04 2 –4.31 ¸ –4.16 –4.01
Most sensitive cell lines (logGI50/logTGI): CCRF-CEM –4.66/> –4.00; SR –5.14/–4.70 (L); HOP-92 –5.22/–4.62; 
NCI-H226 –4.58/> –4.00 (NSCLC); SF-295 –4.51/> –4.00; SNB-75 –5.57/–4.78; U251 –5.03/–4.20 (CNS); 
SK-OV-3 –4.71/–4.09 (OC); 786-O –4.66/> –4.00 (RC); MDA-MB-231/ATTC –4.80/> –4.00; HS-578 –4.73/–4.04 (BC) 
12 11 –6.71 ¸ –4.15 –4.11 1 – –4.00 0 – 4.00
Most sensitive cell lines (logGI50/logTGI): CCRF-CEM –6.71/> –4.00  (L); U251 –4.51/> –4.00 (CNS) 
13 20 –4.66 ¸ > –4.06 –4.13 2 –4.43 ¸ –4.28 –4.01 1 –4.11 ¸ –4.00 –4.00
Most sensitive cell lines (logGI50/logTGI): SR  –4,47/> –4.00 (L); NCI-H23 –4.50/> –4.00; A-498 –4.75/–4.43 (NSCLC); 
MDA-MB-231/ATTC –4.58/> –4.00; HS-578T –4.66/–4.28 (BC)
14 36 –8.00 ¸ –4.03 –4.53 11 –5.16 ¸ –4.11 –4.10 4 –4.55 ¸ –4.05 –4.02
Most sensitive cell lines (logGI50/ logTGI): CCRF-CEM –4.87/> –4.00; MOLT–4  –5.60/> –4.00; RPMI-8226  –8.00/–5.16
(L); A549/ATTC –4.97/> –4.00; HOP-62 –4.90/–4.53. HOP-92 –5.27/–4.54; NCI-H226 –4.88/–4.33 (NSCLC); 
HCT-116  –4.86/–4.18 (CC);  M14 –4.84/> –4.00 (M); 786-O  –4.86/–4.45; ACHN –4.84/–4.54. SN12C –4.92/–4.46 (RC);
MDA-MB-231/ATTC –5.34/–4.64; HS578T –4.98/–4.11 (BC)
15 1 –8.00 ¸ –4.00 –4.07 1 –4.02 –4.00 – – –4.00
Most sensitive cell lines (logGI50/logTGI): HOP-92 < –8.00/–4.02 (NSCLC)
16 48 –5.55 ¸ –4.30 –4.66 36 –4.65 ¸ –4.30 –4.26 18 –4.33 ¸ –4.03 –4.07
Most sensitive cell lines (logGI50/logTGI): NCI-H522 –5.55/> –4.00 (NSCLC); U251 –4.91/–4.61(CNS);  
PC-3 –4.87/–4.52 (PC) 
17 40 –5.39 ¸ –4.20 –4.41 13 –4.30 ¸ –4.06 –4.04 1 –4.26 ¸ –4.00 –4.00
Most sensitive cell lines (logGI50/logTGI): CCRF-CEM –5.39/> –4.00; K-562 –5.04/> –4.00; MOLT-4 –5.33/> –4.00 (L)
18 46 –6.30 ¸ –4.06 –4.55 23 –4.55 ¸ –4.04 –4.16 8 –4.27 ¸ –4.10 –4.03
Most sensitive cell lines (logGI50/logTGI): NCI-H23 –4.89/–4.55 (NSCLC); NCI-H522 –6.30/> –4.00 
19 8 –4.54 ¸ –4.16 –4.04 – – –4.00 – – –4.00
Most sensitive cell lines (logGI50/logTGI): MALME-3M –4.54/> –4.00 (M)
20 55 –4.78 ¸ –4.10 –4.56 31 –4.39 ¸ –4.07 –4.13 5 –4.19 ¸ –4.03 –4.01
Most sensitive cell lines (logGI50/logTGI): SK-MEL-5 –4.78/–4.48; UACC-62 –4.74/–4.39 (M)
21 56 –5.78 ¸ –4.87 –5.31 52 –5.38 ¸ –4.02 –4.67 22 –4.80 ¸ –4.04 –4.12
Most sensitive cell lines (logGI50/ logTGI): HL-60(TB) –5.66/–5.23; K-562 –5.43/–4.77 (L);  NCI-H522 –5.78/–5.38
(NSCLC); KM12 –5.62/–5.18 (CC)
22 56 –5.29 ¸ –4.03 –4.74 43 –4.63 ¸ –4.12 –4.28 13 –4.18 ¸ –4.04 –4.03
Most sensitive cell lines (logGI50/ logTGI): CCRF-CEM –5.18/–4.34; SR –5.18/–4.49 (L); KM12 –5.11/–4.63 (CC); U251
–5.10/–4.61 (CNS); ÐÑ-3 –5.29/–4.56 (PC)
23 21 –4.90 ¸ –4.30 –4.42 3 –4.47 ¸ –4.30 –4.31 – > –4.30 –4.30
Most sensitive cell lines (logGI50/ logTGI): EKVX –4.83/–4.39; NCI-H23 –4.75/> –4.30 (NSCLC); SF-268 –4.86/–4.32
(CNS); LOX IMVI –4.90/–4.47 (M)
8
Continuation of Tableserved for 6-[5-(4-nitrobenzylidene)-4-oxo-2-thioxo-
thiazolidin-3-yl]-hexanoic acid, 2-(5-isopropylidene-
2,4-dioxothiazolidin-3-yl)-N-(3-trifluoromethylphe-
nyl)-acetamide influence on 786-O cell. Moreover,
high sensitivity of all leukemia cell lines to studied 4-
azolidinone derivatives was detected.
As the next step 25 compounds were selected for
advanced assays on 60 cell lines panel (at five 10-fold
dilutions – concentrations ranging from 10
–4 to 10
–8 M)
(Fig. 3). Tested compounds belonged to the following
groups (5-aryl(heteryl)idenerhodanine-3-alkanemo-
no(di)carboxylic acids, 5-arylidene-2,4-thiazolidinedi- 
one-3-alkanecarboxylic acids and 5-arylidene-2,4-imi- 
dazolidinedione-3-acetic acids) and showed different
strength of anticancer activity – from practically absent 
to expressive action on all tested cell lines (Table). Ob-
tained data allowed us to summarize some aspects of
structure – anticancer activity relationships in testing
row of 4-azolidinone derivatives. The presence of yli-
dene moiety in position 5 of core heterocycles plays
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1 2 3 4 5 6 7 8 9 10
24 47 –5.32 ¸ –4.16 –4.55 20 –4.35 ¸ –4.16 –4.13 8 –4.21 ¸ –4.02 –4.02
Most sensitive cell lines (logGI50/ logTGI): NCI-H522 –5.32/> –4.00 (NSCLC); SN12C –5.14/–4.08 (RC) 
25 45 –5.24 ¸ –4.44 –4.88 32 –4.88 ¸ –4.34 –4.50 12 –4.56 ¸ –4.34 –4.33
Most sensitive cell lines (logGI50/ logTGI): SR –5.16/–4.72 (L); NCI-H322M –5.03/–4.53; NCI-H522 –5.01/–4.55 (NSCLC);
UACC-62 –5.12/–4.84 (M); OVCAR-8 –5.14/–4.67 (OC);  MDA-MB-435 –5.07/–4.74; MDA-MB-231/ATTC –5.16/–4.64; BT-549
–5.24/–4.88 (BC) 
Ending of Table
aThe value > –4.00 (or  > –4.30) was excluded; *data of double assay;  N 1, N 2, N 3 – number of sensitive cell lines; L – Leukemia; CC –
Colon Cancer; CNS – CNS Cancer; NSCLC – Non–Small Cell Lung Cancer; M – Melanoma; OC – Ovarian Cancer; BC – Breast Cancer;
RC – Renal Cancer; PC – Prostate Cancer.
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Fig. 4. Some structure-anticancer activity relationships aspects (in square grow percent for definite cancer cell lines)crucial role for achieving anticancer activity (Fig. 4).
Presence of certain arylidene or phenylpropenylidene
fragments is also desirable. This confirms our hypo-
thesis about critical influence of the moiety in position
5 of core heterocycles on realization of biological ef-
fects, as it was previously established for another gro-
ups of 4-azolidinone and related heterocyclic systems
derivatives [1, 28]. Comparison of anticancer activity
of free acids and their derivatives (namely amides)
shows that latter are more active than corresponding
acids as well as the results of [35]. CF3-Substituted
anilines and sulfanilamide moieties are desirable as
«privileged» fragments. 
Comparison of anticancer activity of isosters of
rhodanine and 2,4-thiazolidinedione derivatives or
homologs of mentioned substances didn’t allow us to
establish any relation. However, substitution of S-atom 
of thiazolidinone ring for N-atom (transfer from 2,4-
thiazolidinedione to 2,4-imidazolidinedione) contribu- 
tes to increase in anticancer activity and appearing of
selectivity. Hydantoin-3-acetic acids derivatives (14,
8, 9, 11, 12) possess the distinct selective influence on
Leukemia cell lines comparing to the other groups of
cancer cell lines. This fact allows us to interpret the 5-
arylidene-2,4-imidazolidinedione-3-acetic acids ami-
des as lead-compounds in search of antileukemic
agents. In addition, mentioned group is more active in
comparison to other 2,4-thia(imida)zolidinedione deri-
vatives [28]. 
Analysis of anticancer activity data of 5-ylide-
nerhodanine-3-succinic acids derivatives allowed to
summarize some structure-activity correlations (Fig.
5). Modification of free dicarboxylic acids to their
diamides caused increase in anticancer activity, which
was the most prominent for cyclic imides. Based on the
interpretation of obtained data 3-(4-oxo-2-thioxothia-
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Fig. 5. Directions of lead optimization among 5-ylidenerhodanine-3-succinic acids derivativeszolidine-3-yl)-pyrrolidine-2,5-dione fragment was as-
sumed as possible pharmacophore within investigated
samples row [29]. Consequently, we showed the direc-
tions of this fragment chemical modification aimed at
structure optimization, namely: position C5 of rhodani- 
ne cycle and N-atom of pyrrolidine.
Conclusion. The present study describes in vitro
anticancer activity of new 5-ylidene-4-thiazolidinone-
3-alkanecarboxylic acids derivatives. The series of
active compounds with high activity and/or selectivity
levels were selected. Some aspects of structure–an-
ticancer activity relationships were determined and
structure design directions were proposed. 5-Ary-
lidenehydantoin-3-acetic acids derivatives were iden-
tified as a new class of potent antileukemic agents.
Possible pharmacophore scaffold of 5-ylidenerhoda-
nine-3-succinic acids derivatives was suggested.
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Ä. Â. Êàìiíñüêèé, Ð. Á. Ëå  ñèê
Âçàºìîç â’ÿ çîê  «ñòðóê òó ðà–ïðî òè ðà êî âà  àê òèâí³ñòü»  â  ðÿäó  4-
àçîë³äîí-3-êàð áî íî âèõ  êèñ ëîò  òà  ¿õí³õ  ïîõ³äíèõ
Ðå çþ ìå 
Ìåòà  äà íî ãî  äîñë³äæåí íÿ  ïî ëÿ ãà ëà  ó  âèâ ÷åíí³  ïðî òè ðà êî âî¿
àê òèâ íîñò³  4-àçîë³äîí-3-êàð áî íî âèõ  êèñ ëîò  òà  ¿õí³õ  ïîõ³äíèõ,
âñòà íîâ ëåíí³  îñîá ëè âîñ òåé  âçàºìîç â’ÿç êó  «ñòðóê òó ðà–àê -
òèâí³ñòü».  Ìå òî äè. Îðãàí³÷íèé ñèí  òåç, ñïåê  òðàëüí³ ìå  òî  äè,
ñêðèí³íã  ïðî òè ïóõ ëèí íî¿  àê òèâ íîñò³  (US  NCI-ìå òî äî ëîã³¿,
Developmental Therapeutic Program). Ðå çóëü òà òè. Ïðåä  ñòàâ  -
ëå íî  ðå çóëü òà òè  òåñ òó âàí íÿ  in  vitro  ïðî òè ðà êî âî¿  àê òèâ -
íîñò³  íî âèõ  ïîõ³äíèõ  4-àçîë³äîí-3-àë êàí êàð áî íî âèõ  êèñ ëîò.
Âèä³ëåíî  âè ñî êî àê òèâí³  ñïî ëó êè,  ÿê³  íà ëå æàòü  äî  ïîõ³äíèõ
5-àðèë³äåí-2,4-ò³à(³ì³äà)çîë³äîí-3-àë êàí êàð áî íî âèõ  êèñ ëîò
òà  5-àðèë(ãå òå ðèë)³äåí ðî äàí³í-3-ñóê öè íàò íèõ  êèñ ëîò.  Âñòà -
íîâ ëåí³ çà êî íîì³ðíîñò³  çà ëåæ íîñò³  «ñòðóê òó ðà–àê òèâí³ñòü» 
äîç âî ëÿ þòü  îêðåñ ëè òè  íà ïðÿì êè  îïòèì³çàö³¿  ñòðóê òóð-
ë³äåð³â  ³  ³äåí òèô³êó âà òè  ìî ëå êó ëÿðí³  ôðàã ìåí òè  äëÿ  äèç àé íó
ïî òåíö³éíèõ  ïðî òè ðà êî âèõ  àãåíò³â  íà  îñíîâ³  4-àçîë³äî íî âî ãî
ñêàô ôîë äó.  Àì³äè  5-àðèë³äåíã³äàí òî¿í-3-îöòî âèõ  êèñ ëîò  âè-
çíà  ÷å  íî ÿê íî  âèé êëàñ ïðî  òè  ëåé  êåì³÷íèõ àãåíò³â. Äëÿ 5-³ë³äåí  -
ðî äàí³í-3-ñóê öè íàò íèõ  êèñ ëîò  ³äåí òèô³êî âà íî  éìîâ³ðíèé
ôàð ìà êî ôîð. Âèñ íîâ êè. Îäåð æà íî íèç êó àê òèâ íèõ ñïî ëóê ç âè -
ñî êèì ð³âíåì ïðî òè ðà êî âî¿ àê òèâ íîñò³ òà/àáî ñå ëåê òèâ íîñò³. 
Çàï ðî ïî íî âà íî  íà ïðÿì êè  äèç àé íó  ñòðóê òó ðè  ïî òåíö³éíèõ  ïðî -
òè ðà êî âèõ  àãåíò³â  íà  îñíîâ³  âñòà íîâ ëå íèõ  çà êî íîì³ðíîñ òåé
«ñòðóê òó ðà–àê òèâí³ñòü».
Êëþ ÷îâ³  ñëî âà:  4-àçîë³äîí-3-êàð áî íîâ³  êèñ ëî òè,  ïðî òè ðà êî âà
àê òèâí³ñòü,  âçàºìîç â’ÿ çîê  «ñòðóê òó ðà–àê òèâí³ñòü».
Ä. Â. Êà  ìèí  ñêèé, Ð. Á. Ëå  ñûê
Âçà è ìîñ âÿçü  «ñòðóê òó ðà–ïðî òè âî î ïó õî ëå âàÿ  àê òèâ íîñòü»  â
ðÿäó  4-àçî ëè äîí-3-êàð áî íî âûõ  êèñ ëîò  è  èõ  ïðî èç âîä íûõ
Ðå çþ ìå
Öåëü  äàí íî ãî  èñ ñëå äî âà íèÿ  ñî ñòî ÿ ëà  â  èç ó÷å íèè  ïðî òè âî î ïó -
õî ëå âîé àê òèâ íîñ òè 4-àçî ëè äîí-3-êàð áî íî âûõ êèñ ëîò è èõ ïðî -
èç âîä íûõ,  à  òàê æå  â  óñòà íîâ ëå íèè  íå êî òî ðûõ  îñî áåí íîñ òåé
âçà è ìîñ âÿ çè  «ñòðóê òó ðà–àê òèâ íîñòü».  Ìå òî äû.  Îðãà íè ÷åñ -
êèé  ñèí òåç,  ñïåê òðàëü íûå  ìå òî äû,  ñêðè íèíã  ïðî òè âî î ïó õî ëå -
âîé  àê òèâ íîñ òè  (US  NCI-ìå òî äî ëî ãèÿ,  Developmental  The-
rapeutic Program). Ðå çóëü òà òû.  Ïðåä ñòàâ ëå íû  ðå çóëü òà òû
òåñ òè ðî âà íèÿ  in  vitro  ïðî òè âî î ïó õî ëå âîé  àê òèâ íîñ òè  íî âûõ
ïðî èç âîä íûõ  4-àçî ëè äîí-3-àëàí êàð áî íî âûõ  êèñ ëîò.  Îòîá ðà íû 
íà è áî ëåå  àê òèâ íûå  ñî å äè íå íèÿ,  êî òî ðûå  îò íî ñÿò ñÿ  ê  ïðî èç -
âîä íûì  5-àðè ëè äåí-2,4-òèà(èìè äà)çî ëè äîí-3-àë êàí êàð áî íî -
âûõ  êèñ ëîò  è  5-àðèë(ãå òå ðèë)èäåí ðî äà íèí-3-ñóê öè íàò íûõ
êèñ ëîò.  Íà  îñíî âà íèè  âû ÿâ ëåí íûõ  çà êî íî ìåð íîñ òåé  âçà è ìîñ -
âÿ çè  «ñòðóê òó ðà–àê òèâ íîñòü»  îïðå äå ëå íû  íà ïðàâ ëå íèÿ  îïòè -
ìè çà öèè  ñòðóê òóð-ëè äå ðîâ,  èäåí òè ôè öè ðî âà íû  ìî ëå êó ëÿð íûå
ôðàã ìåí òû  äëÿ  äèç àé íà  ïî òåí öè àëü íûõ  ïðî òè âî î ïó õî ëå âûõ
àãåí òîâ  íà  îñíî âà íèè  4-àçî ëè äî íî âî ãî  ñêàô ôîë äà.  Àìèäû  5-
àðè ëè äåí ãè äàí òî èí-3-óêñóñ íûõ  êèñ ëîò  ðàñ ñìàò ðè âà þò ñÿ  êàê
íî âûé  êëàññ  ïðî òè âî ëåé êå ìè ÷åñ êèõ  àãåí òîâ.  Äëÿ  ðÿäà  5-èëè -
äåí ðî äà íèí-3-ñóê öè íàò íûõ  êèñ ëîò  óñòà íîâ ëåí  âå ðî ÿò íûé
ôàð ìà êî ôîð.  Âû âî äû. Âû äå ëåí ðÿä àê òèâ íûõ ñî å äè íå íèé ñ âû -
ñî êèì  óðîâ íåì  ïðî òè âî î ïó õî ëå âîé  àê òèâ íîñ òè  è/èëè  ñå ëåê -
òèâ íîñ òè.  Ïðåä ëî æå íû  íà ïðàâ ëå íèÿ  äèç àé íà  ñòðóê òó ðû
ïî òåí öè àëü íûõ  ïðî òè âî î ïó õî ëå âûõ  àãåí òîâ  íà  îñíî âå  óñòà -
íîâ ëåí íûõ  çà êî íî ìåð íîñ òåé  «ñòðóê òó ðà–àê òèâ íîñòü».
Êëþ ÷å âûå  ñëî âà:  4-àçî ëè äîí-3-êàð áî íî âûå  êèñ ëî òû,  ïðî -
òè âî î ïó õî ëå âàÿ  àê òèâ íîñòü,  âçà è ìîñ âÿçü  «ñòðóê òó ðà–àê òèâ -
íîñòü».
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